FDA Class II Recall: Johnson, S C and Son, Inc. Sunscreen Contamination Prompts Market Withdrawal
Johnson, S C and Son, Inc. has initiated a Class II recall of 493,462 units of Kids by babyganics SPF 50 mineral sunscreen due to chemical contamination. This voluntary action, impacting US and Canadian markets, necessitates immediate review by procurement and regulatory teams. The event underscores critical supply chain vigilance for OTC drug products, particularly those with active ingredients like titanium dioxide and zinc oxide.
FDA Initiates Class II Recall: Johnson, S C and Son, Inc.'s Mineral Sunscreen Contamination
ChemLifeIntel confirms that Johnson, S C and Son, Inc., operating from Racine, WI, United States (postal code 53403-2237), has initiated a voluntary Class II recall of 493,462 units of its Kids by babyganics SPF 50 mineral sunscreen. This significant market action, designated recall number D-0276-2025, commenced on February 13, 2025, following the identification of chemical contamination within the product. The affected sunscreen, distributed by KAS Direct LLC from the same Racine address, contains titanium dioxide (3.5%) and zinc oxide (7.25%) as active ingredients, packaged in 3 OZ spray bottles. The recall spans both the United States and Canadian markets, indicating a broad distribution footprint that requires immediate attention from procurement and regulatory teams across North America. For your business, this means a direct impact on product availability and potential reputational risks if your supply chain is exposed to these specific product lots. The Class II classification signifies that the contaminated product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates a swift and thorough response from any entity involved in the distribution or sale of these products. The specific UPCs identified are 813277019916 and 813277019923, encompassing numerous lot numbers with expiration dates ranging from February 2025 to June 2026. Procurement directors must immediately cross-reference these identifiers against current inventory and distribution records to prevent further circulation of the compromised product.
Strategic Implications of Chemical Contamination in OTC Mineral Sunscreens
The chemical contamination event affecting Johnson, S C and Son, Inc.'s Kids by babyganics SPF 50 mineral sunscreen carries substantial strategic implications for all stakeholders in the over-the-counter (OTC) drug and personal care sectors. Mineral sunscreens, relying on active ingredients like titanium dioxide and zinc oxide, are increasingly favored by consumers for their perceived natural and broad-spectrum protection. This recall highlights a critical vulnerability in the supply chain for these key active pharmaceutical ingredients (APIs) and excipients. Chemical contamination, regardless of its source—be it raw material impurity, manufacturing process deviation, or packaging interaction—can compromise product safety and efficacy, leading to significant regulatory consequences and consumer distrust. For procurement directors, this event underscores the imperative for stringent supplier qualification and ongoing monitoring, particularly for API manufacturers and formulators of finished OTC products. The purity and quality of titanium dioxide (HSN 2823.00) and zinc oxide (HSN 2817.00) must be verified through robust analytical testing protocols. Regulatory affairs heads must re-evaluate their quality management systems and risk assessment frameworks to proactively identify and mitigate potential contamination pathways. Business development executives should note the potential for market shifts as consumers and regulators increase scrutiny on product safety, potentially favoring brands with demonstrably superior quality control. This incident serves as a stark reminder that even voluntary recalls of seemingly low-risk products can have far-reaching commercial and regulatory repercussions.
Navigating Regulatory Scrutiny: Compliance and Risk Mitigation for Consumer Health Products
The ongoing Class II recall by Johnson, S C and Son, Inc. for chemical contamination in an OTC drug product signals heightened regulatory scrutiny for the consumer health industry. While firm-initiated and voluntary, the FDA's classification as Class II indicates a non-trivial risk profile that demands a comprehensive response. For regulatory affairs teams, this means ensuring immediate compliance with recall procedures, including effective communication with distributors and retailers in both the United States and Canada, as per the product's distribution pattern. The firm's ability to swiftly identify the issue and initiate the recall is a positive, but the underlying cause of contamination will be subject to intense review. This event should prompt supply chain VPs to conduct internal audits of their own product portfolios, especially those containing similar mineral active ingredients or manufactured through comparable processes. The broader regulatory environment, as evidenced by recent parallel events such as Essential Wellness Pharma's Class II recall of progesterone injection due to sterility failure, indicates a consistent focus by the FDA on manufacturing quality and product integrity across diverse drug categories. Proactive risk mitigation strategies, including enhanced raw material testing, robust in-process controls, and comprehensive finished product release testing, are essential to prevent similar incidents. Failure to demonstrate adequate control over product quality can lead to more severe regulatory actions, including potential import alerts or mandatory recalls, significantly disrupting market access and brand equity.